Arsenic Decreases RXRα-dependent Transcription of CYP3A and Suppresses Immune Regulators in Hepatocytes

Overview

Journal Int Immunopharmacol

Specialties Allergy & Immunology
Pharmacology

Date 2012 Feb 8

PMID 22310326

Citations 4

Authors

Trisha L Noreault-Conti

Abigail Fellows

Judith M Jacobs

Heidi W Trask

Stephen C Strom

Ronald M Evans

Steven A Wrighton

Peter R Sinclair

Jacqueline F Sinclair

Ralph C Nichols

Affiliations

Soon will be listed here.

Abstract

Arsenite is critical pharmacologically as a treatment for advanced stage blood cancer. However, environmental exposure to arsenic results in multiple diseases. Previous studies have shown that arsenic decreases expression of CYP3A, a critical drug metabolizing enzyme in human and rat liver. In addition, acute and chronic arsenic exposure in liver stimulates an inflammatory response. Our work has shown that arsenite decreases nuclear levels of RXRα the nuclear receptor that, as a heterodimer partner with PXR, transactivates the CYP3A gene. These results suggest that arsenite decreases transcription of CYP3A by decreasing RXRα. The present report shows that exposure to 5 μM arsenite decreased the activity of a rat CYP3A promoter luciferase reporter in HepG2 cells. The activity of a RARE-luciferase reporter, that is transactivated by the retinoic acid receptor (RAR)/RXRα, was also decreased. Previous studies have shown that arsenic in the concentration range of 2-5 μM affects CYP3A mRNA. When rifampicin-treated primary human hepatocyte cultures were exposed to arsenite concentrations as low as 50 nM, CYP3A mRNA was decreased. Treatment of primary human hepatocytes with the proteasome inhibitor MG132 increased RXRα suggesting the involvement of the proteasome pathway in regulation of RXRα. Finally, arsenic induces a pro-inflammatory response in liver. Surprisingly, we show that in hepatocytes arsenite decreases expression of two inflammatory mediators, TNF and VEGF, an effect that is not predicted from suppression of RXRα activity.

Citing Articles

Arsenic: A Perspective on Its Effect on Pioglitazone Bioavailability.

Terrones-Gurrola M, Ponce-Pena P, Salas-Pacheco J, Camacho-Luis A, de Jesus Pozos-Guillen A, Nieto-Delgado G Int J Environ Res Public Health. 2023; 20(3).

PMID: 36767268 PMC: 9915544. DOI: 10.3390/ijerph20031901.

Role of nuclear receptor PXR in immune cells and inflammatory diseases.

Sun L, Sun Z, Wang Q, Zhang Y, Jia Z Front Immunol. 2022; 13:969399.

PMID: 36119030 PMC: 9481241. DOI: 10.3389/fimmu.2022.969399.

Arsenic: Various species with different effects on cytochrome P450 regulation in humans.

El-Ghiaty M, El-Kadi A EXCLI J. 2021; 20:1184-1242.

PMID: 34512225 PMC: 8419240. DOI: 10.17179/excli2021-3890.

Retinoid-xenobiotic interactions: the Ying and the Yang.

Shmarakov I Hepatobiliary Surg Nutr. 2015; 4(4):243-67.

PMID: 26311625 PMC: 4526766. DOI: 10.3978/j.issn.2304-3881.2015.05.05.

References

Bastien J, Rochette-Egly C . Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004; 328:1-16. DOI: 10.1016/j.gene.2003.12.005. View

Boudjelal M, Wang Z, Voorhees J, Fisher G . Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes. Cancer Res. 2000; 60(8):2247-52. View

Nevens F, Fevery J, Van Steenbergen W, Sciot R, Desmet V, De Groote J . Arsenic and non-cirrhotic portal hypertension. A report of eight cases. J Hepatol. 1990; 11(1):80-5. DOI: 10.1016/0168-8278(90)90276-w. View

Hall M, Chen Y, Ahsan H, Slavkovich V, van Geen A, Parvez F . Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology. 2006; 225(2-3):225-33. DOI: 10.1016/j.tox.2006.06.010. View

Centeno J, Mullick F, Martinez L, Page N, Gibb H, Longfellow D . Pathology related to chronic arsenic exposure. Environ Health Perspect. 2002; 110 Suppl 5:883-6. PMC: 1241266. DOI: 10.1289/ehp.02110s5883. View

Strom S, Pisarov L, Dorko K, Thompson M, Schuetz J, Schuetz E . Use of human hepatocytes to study P450 gene induction. Methods Enzymol. 1996; 272:388-401. DOI: 10.1016/s0076-6879(96)72044-x. View

Arkusz J, Stanczyk M, Lewiniska D, Stepnik M . Modulation of murine peritoneal macrophage function by chronic exposure to arsenate in drinking water. Immunopharmacol Immunotoxicol. 2005; 27(2):315-30. DOI: 10.1081/iph-200067947. View

Wrighton S, Vandenbranden M, Ring B . The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm. 1996; 24(5):461-73. DOI: 10.1007/BF02353474. View

Moreau A, Vilarem M, Maurel P, Pascussi J . Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm. 2007; 5(1):35-41. DOI: 10.1021/mp700103m. View

10.

Xie W, Barwick J, Downes M, Blumberg B, Simon C, Nelson M . Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 2000; 406(6794):435-9. DOI: 10.1038/35019116. View

11.

Kopf E, Plassat J, Vivat V, de The H, Chambon P, Rochette-Egly C . Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. J Biol Chem. 2000; 275(43):33280-8. DOI: 10.1074/jbc.M002840200. View

12.

Das S, Santra A, Lahiri S, Guha Mazumder D . Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol. 2005; 204(1):18-26. DOI: 10.1016/j.taap.2004.08.010. View

13.

Hughes M, Beck B, Chen Y, Lewis A, Thomas D . Arsenic exposure and toxicology: a historical perspective. Toxicol Sci. 2011; 123(2):305-32. PMC: 3179678. DOI: 10.1093/toxsci/kfr184. View

14.

Neshiwat L, Friedland M, Feldman S, Glucksman W, Russo Jr R . Hepatic angiosarcoma. Am J Med. 1992; 93(2):219-22. DOI: 10.1016/0002-9343(92)90054-f. View

15.

Rochette-Egly C . Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 2003; 15(4):355-66. DOI: 10.1016/s0898-6568(02)00115-8. View

16.

Hollingshead H, Killins R, Borland M, Girroir E, Billin A, Willson T . Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis. 2007; 28(12):2641-9. DOI: 10.1093/carcin/bgm183. View

17.

Lin R, Evans R . Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000; 5(5):821-30. DOI: 10.1016/s1097-2765(00)80322-6. View

18.

Jacobs J, Nichols C, Andrew A, Marek D, Wood S, Sinclair P . Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol. 1999; 157(1):51-9. DOI: 10.1006/taap.1999.8659. View

19.

Wrighton S, Schuetz E, Thummel K, Shen D, Korzekwa K, Watkins P . The human CYP3A subfamily: practical considerations. Drug Metab Rev. 2001; 32(3-4):339-61. DOI: 10.1081/dmr-100102338. View

20.

Vakharia D, Liu N, Pause R, Fasco M, Bessette E, Zhang Q . Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepatocyte cultures. Toxicol Appl Pharmacol. 2001; 170(2):93-103. DOI: 10.1006/taap.2000.9087. View